Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18024239 | 0.81 | SLC6A4 (0.49) | SLC6A3SLC6A4SLC6A2MAPK1HRH3 | |
| SCHEMBL23993627 | 0.80 | HTR2A (0.49) | SLC6A3SLC6A4SLC6A2KDM1A | |
| SCHEMBL16649529 | 0.79 | SLC6A2 (0.48) | SLC6A3SLC6A4SLC6A2MAPK1KDM1A | |
| SCHEMBL12498977 | 0.79 | SLC6A2 (0.48) | SLC6A3SLC6A4SLC6A2MAPK1KDM1A | |
| SCHEMBL21393203 | 0.79 | SLC6A4 (0.43) | SLC6A3SLC6A4SLC6A2MAPK1KDM1A | |
| SCHEMBL21038118 | 0.77 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2MAPK1HRH3 | |
| SCHEMBL18022538 | 0.77 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2MAPK1HRH3 | |
| SCHEMBL18745056 | 0.74 | HTR2A (0.50) | SLC6A3SLC6A4SLC6A2MAPK1 | |
| SCHEMBL16690753 | 0.74 | SLC6A2 (0.43) | SLC6A3SLC6A4SLC6A2MAPK1 | |
| SCHEMBL17460930 | 0.73 | HTR2A (0.43) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | SLC6A3 4451/4885SLC6A4 4637/4885SLC6A2 4572/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SLC6A3 4451/4885SLC6A4 4637/4885SLC6A2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.